A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer

NCT02711553 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

309

Enrollment

INDUSTRY

Sponsor class

Conditions

Biliary Tract Cancer
Metastatic Cancer
Advanced Cancer

Interventions

DRUG: Ramucirumab
DRUG: Merestinib
DRUG: Cisplatin
DRUG: Gemcitabine
DRUG: Placebo Oral
DRUG: Placebo IV

Sponsor

Eli Lilly and Company